Skip to main content
SpringerLink
Log in
Book cover

Inflammation in the Pathogenesis of Chronic Diseases pp 93–126Cite as

Cyclooxygenase-2 (COX-2) and the Inflammogenesis of Cancer

  • Chapter

Part of the book series: Subcellular Biochemistry ((SCBI,volume 42))

Cohesive scientific evidence from molecular, animal, and human investigations supports the hypothesis that aberrant induction of COX-2 and up-regulation of the prostaglandin cascade play a significant role in carcinogenesis, and reciprocally, blockade of the process has strong potential for cancer prevention and therapy. Supporting evidence includes the following: [1] expression of constitutive COX-2-catalyzed prostaglandin biosynthesis is induced by most cancer-causing agents including tobacco smoke and its components (polycylic aromatic amines, heterocyclic amines, nitrosamines), essential polyunsaturated fatty acids (unconjugated linoleic acid), mitogens, growth factors, proinflammatory cytokines, microbial agents, tumor promoters, and other epigenetic factors, [2] COX-2 expression is a characteristic feature of all premalignant neoplasms, [3] COX-2 expression is a characteristic feature of all malignant neoplasms, and expression intensifies with stage at detection and cancer progression and metastasis, [4] all essential features of carcinogenesis (mutagenesis, mitogenesis, angiogenesis, reduced apoptosis, metastasis, and immunosuppression) are linked to COX-2-driven prostaglandin (PGE-2) biosynthesis, [5] animal studies show that COX-2 up-regulation (in the absence of genetic mutations) is sufficient to stimulate the transformation of normal cells to invasive cancer and metastatic disease, [6] non-selective COX-2 inhibitors, such as aspirin and ibuprofen, reduce the risk of human cancer and precancerous lesions, and [7] selective COX-2 inhibitors, such as celecoxib, reduce the risk of human cancer and precancerous lesions at all anatomic sites thus far investigated. Results confirming that COX-2 blockade is effective for both cancer prevention and therapy have been tempered by observations that some COX-2 inhibitors pose a risk to the cardiovascular system, and more studies are needed in order to determine if certain of these drugs can be taken at dosages that prevent cancer without increasing cardiovascular risk. It is emphasized that the "inflammogenesis model of cancer" is not mutually exclusive and may in fact be synergistic with the accumulation of somatic mutations in tumor suppressor genes and oncogenes or epigenetic factors in the development of cancer

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahmedin J, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics, 2006. CA Cancer J Clin 56: 106–130, 2006.

    Google Scholar 

  2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (5): 759–767, 1990.

    Article  PubMed  CAS  Google Scholar 

  3. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1 (2): 157–162, 2001.

    Article  PubMed  CAS  Google Scholar 

  4. Soto AM, Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? Biosessays 26 (10): 1097–1107, 2004.

    Article  CAS  Google Scholar 

  5. Lijinsy W. A view of the relation between carcinogenesis and mutagenesis. Environ Mol Mutagen 14 (16): 78–84, 1989.

    Article  Google Scholar 

  6. Prehn RT. Cancers beget mutations versus mutations beget cancers. Cancer Research 54: 5296–5300,(1994).

    PubMed  CAS  Google Scholar 

  7. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 100: 776–781, 2003.

    Article  PubMed  CAS  Google Scholar 

  8. Verma M, Maruvada P, Srivastara S. Epigenetics and cancer. Crit Rev Clin Lab Sci 41: 5–6, 2004.

    Google Scholar 

  9. Momparler RL. Cancer epigenetics. Oncogene 22(42): 6479–6483, 2003.

    Article  PubMed  CAS  Google Scholar 

  10. Virchow R. Reizung and Reizbarkeit. Arch Pathol Anat Klin Med 14: 1–63, 1858.

    Article  Google Scholar 

  11. Virchow R. Aetiologie der neoplastischen Geschwulst/Pathogenie der neoplastischen Geschwulste. In: Die Krankhaften Geschwulste. Berlin: Verlag von August Hirschwald, pp. 57–101, 1863.

    Google Scholar 

  12. Balkwill F, Mantovani A. Inflammationand cancer: back to Virchow? Lancet 357: 539–545, 2001.

    Article  PubMed  CAS  Google Scholar 

  13. Schrieber H, Rowley DA. Inflammation and cancer. In: JI Gallin, R Snyderman, eds. Inflammation: Basic Principles and Clinical Correlates, third ed. Philadelphia: Lippincott Williams & Wilkins, pp. 1117–1129, 1999.

    Google Scholar 

  14. Coussens LM, Werb Z. Inflammation and cancer. Nature 420: 860–867, 2002.

    Article  PubMed  CAS  Google Scholar 

  15. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology 14: 433–439, 2004.

    Article  PubMed  CAS  Google Scholar 

  16. Herschman HR. Historical Aspects of COX-2. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, 2002.

    Google Scholar 

  17. Koki AT, Leahy KM, Harmon JM, Masferrer JL. Cyclooxygenase-2 and cancer. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, 2002.

    Google Scholar 

  18. Harris RE. Cyclooxygenase-2 blockade in cancer prevention and therapy: widening the scope of impact. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, 2002.

    Google Scholar 

  19. Robbins SL, Cotran RS. Pathologic Basis of Disease. 2nd edn, WB Saunders Company, Philadelphia, PA, 1979.

    Google Scholar 

  20. Kumar V, Fausto N, Abbas AK. Robbins and Cotran Pathologic Basis of Disease. 7th edn, WB Saunders Company, Philadelphia, PA, 2004.

    Google Scholar 

  21. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188, 1994.

    PubMed  CAS  Google Scholar 

  22. Sano H, Kawahito Y, Wilder RR, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in colorectal cancer. Cancer Res 55: 3785–3789, 1995.

    PubMed  CAS  Google Scholar 

  23. Dubois RN, Smalley WE. Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterology 31: 898–906, 1996.

    Article  CAS  Google Scholar 

  24. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. International Journal of Oncology 10: 503–507, 1997.

    CAS  Google Scholar 

  25. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90 (6): 455–460, 1998.

    Article  PubMed  CAS  Google Scholar 

  26. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adnocarcinoma sequence. Am J Gastroenterol 96 (4): 991–996, 2001.

    Google Scholar 

  27. Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, Martin A, Flejou JF. Cyclooxygenase-2 is expressed frequently and early in Barrett’s eosophagus and associated adenocarcinoma. Histopathology 42 (5): 457–465, 2003.

    Article  PubMed  CAS  Google Scholar 

  28. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A. Prognostic significance of elevated cyyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Z Gastroenterol 41 (7): 678–681, 2003.

    Google Scholar 

  29. Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res (3): 558–561, 2001.

    Google Scholar 

  30. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6 (6): 2424–2430, 2000.

    PubMed  CAS  Google Scholar 

  31. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59 (22): 5647–5650, 1999.

    PubMed  CAS  Google Scholar 

  32. Oku S, Higashi M, Imazono Y, Sueyoshi K, Enokida H, Kubo H, Yonezawa S, Shirahama T. Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract. BJU Int 91 (1): 109–114, 2003.

    Article  PubMed  CAS  Google Scholar 

  33. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 94 (2): 253–258, 2006.

    Article  PubMed  CAS  Google Scholar 

  34. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista ZC, Vetrani A, Tonini G, Rabitti C. Cox-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinico-pathological features. Histopathology 46 (5): 561–568, 2005.

    Article  PubMed  CAS  Google Scholar 

  35. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90 (2): 423–429, 2004.

    Article  PubMed  CAS  Google Scholar 

  36. Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I, Markaki S, Keramopoulous A. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 72 (5): 241–249, 2005.

    Article  PubMed  CAS  Google Scholar 

  37. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 208 (3): 356–363, 2006.

    Article  PubMed  CAS  Google Scholar 

  38. Hartmann LC, Lingle W, Frost MH, Shaun D, Maloney RA, Vierkant V, Pankratz S, Tisty T, Degnim AC, Visscher DW. COX-2 expression in atypia: correlation with breast cancer risk. Abstract No. 2353, American Association for Cancer Research, 97th Annual Meeting, 2006.

    Google Scholar 

  39. Kim JY, Lim SJ, Park K, Lee CM, Kim J. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 97 (2): 337–341, 2005.

    Article  PubMed  CAS  Google Scholar 

  40. Farley J, Uyehara C, Hashiro G, Belnap C, Birrer M, Salminen E. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol 92 (2): 596–602, 2004.

    Article  PubMed  CAS  Google Scholar 

  41. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix. J Clin Endocrinol Metab 86 (5): 2243–2249, 2001.

    Article  PubMed  CAS  Google Scholar 

  42. Lee JS, Choi YD, Lee JH, Nam JH, Choi C, Lee MC, Parck CS, Juhng SW, Kim HS, Min KW. Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth. Gynecol Oncol 95 (3): 523–529, 2004.

    Article  PubMed  CAS  Google Scholar 

  43. Chen HH, Su WC, Chou CY, Gui HR, Ho SY, Que J, Lee WY. Increased expression of nitric oxide synthase and cylooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 63 (4): 1093–1100, 2005.

    Article  PubMed  CAS  Google Scholar 

  44. Manchana T, Triratanachat S, Sirisabya N, Vasuratna A, Termrungruanglert W, Tresukosol D. Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer. Gynecol Oncol 100 (3): 556–560, 2006.

    Article  PubMed  CAS  Google Scholar 

  45. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7 (2): 429–434, 2001.

    PubMed  CAS  Google Scholar 

  46. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer JL, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (12): 2637–2645, 2000.

    Article  PubMed  CAS  Google Scholar 

  47. Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 36 (8): 865–869, 2001.

    Article  PubMed  CAS  Google Scholar 

  48. Nasir A, Kaiser HE, Boulware D, Hakam A, Zhao H, Yeatman T, Barthel J, Coppola D. Cyclooxygenase-2 expression in right and left-sided colon cancer. Clin Colorectal Cancer 3 (4): 243–247, 2004.

    PubMed  CAS  Google Scholar 

  49. Soumaoro LT, Uetake H, Takagi Y, Iida S, Higuchi T, Yasuno M, Enomoto M, Sugihara K. Co-expression of VEGF-C and COX-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 49 (3): 393–398, 2006.

    Article  Google Scholar 

  50. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58 (17): 3761–3764, 1998.

    PubMed  CAS  Google Scholar 

  51. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58 (22): 4997–5001, 1998.

    PubMed  CAS  Google Scholar 

  52. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7 (4): 861–867, 2001.

    PubMed  CAS  Google Scholar 

  53. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahasi T. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5 (5): 1001–1005, 1999.

    PubMed  CAS  Google Scholar 

  54. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Harris CC. Nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 6 (12): 4739–4744, 2000.

    PubMed  CAS  Google Scholar 

  55. Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 60 (14): 3696–3700, 2000.

    PubMed  CAS  Google Scholar 

  56. Sudbo J, Ristimaki A, Sondresen JE, Kildal W, Goysen M, Koppang HS, Reith A, Risberg B, Nesland JM, Bryne M. Cyclooxygenease-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 39 (5): 497–505, 2003.

    Article  PubMed  CAS  Google Scholar 

  57. Pannone G, Bufo P, Caiaffa MF, Serpco R, Lanza A, Lo Muzio L, Rubini C, Staibano S, Petruzzi M, De Benedictis M, Tursi A, De Rosa G, Macchia L. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopathol Pharmacol 17 (3): 273–282, 2004.

    PubMed  CAS  Google Scholar 

  58. Tang DW, Lin SC, Chang KW, Chi CW, Chang CS, Liu TY. Elevated expression of COX-2 in oral squamous cell carcinoma. J Oral Pathol Med 32 (9): 522–529, 2003.

    Article  PubMed  CAS  Google Scholar 

  59. Chang BW, Kim DH, Kowalski DP, Burleson JA, Son YH, Wilson LD, Haffty BG. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 10 (5): 1678–1684, 2004.

    Article  PubMed  CAS  Google Scholar 

  60. Gupta S. Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73–78, 2000.

    Article  PubMed  CAS  Google Scholar 

  61. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Charui J. Expression of cyclooxygenease-2 in prostate carcinoma. Cancer 89: 589–596, 2000.

    Article  PubMed  CAS  Google Scholar 

  62. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11 (9): 3250–3256, 2005.

    Article  PubMed  CAS  Google Scholar 

  63. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM. HER2 and COX2 expression in human prostate cancer. Eur J Cancer 40 (1): 50–55, 2004.

    Article  PubMed  CAS  Google Scholar 

  64. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 58 (2 Suppl 1): 127–131, 2001.

    Article  PubMed  CAS  Google Scholar 

  65. Masferrer JL, Leahy KM, Koki AT, Aweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (5): 1306–1311, 2000.

    PubMed  CAS  Google Scholar 

  66. Peng JP, Chang HC, Hwang CF, Hung WC. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis. Oral Oncol 41 (9): 903–908, 2005.

    Article  PubMed  CAS  Google Scholar 

  67. Lu H, Gong S. Expression of cyclooxygenase-2 and p53 and their correlation in carcinoma of larynx. Lin Chuang Er Bi Yan Hou Ke Za Zhi 18 (7): 421–423, 2004.

    PubMed  Google Scholar 

  68. Sakamoto T, Kondo K, Yamasoba T, Sugasawa M, Kaga K. Elevated expression of cyclooxygenase-2 in adenocarcinomas of the parotid gland: insights into malignant transformation of pleomorphic adenoma. Ann Otol Rhinol Laryngol 113 (11): 930–935, 2004.

    PubMed  Google Scholar 

  69. Liu J, Yu HG, Yu JP, Wang XL, Zhou XD, Luo HS. Overexpression of cylooxygenase-2 in gastric cancer correlated with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis. Med Oncol 22 (4): 389–397, 2005.

    Article  PubMed  CAS  Google Scholar 

  70. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 11 (20): 7362–7368, 2005.

    Article  PubMed  CAS  Google Scholar 

  71. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ. 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59 (5): 987–990, 1999.

    PubMed  CAS  Google Scholar 

  72. Shiota G, Ikubo M, Noumi T, Goguchi N, Oyama K, Takano Y. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46 (25): 407–412, 1999.

    PubMed  CAS  Google Scholar 

  73. Ferrandina G, Zannoni GF, Ranelletti FO, Legge F, Gessi M, Salutari V, Gallotta V, Lauriola L, Scambia G. Cyclooxygenase-2 expression in borderline ovarian tumors. Gynecol Oncol 95 (1): 46–51, 2004.

    Article  PubMed  CAS  Google Scholar 

  74. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, Mancuso S, Scambia G, Lauriola L. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 95 (4): 801–807, 2002.

    Article  PubMed  CAS  Google Scholar 

  75. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158 (3): 849–853, 2001.

    PubMed  CAS  Google Scholar 

  76. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19 (5): 723–729, 1998.

    Article  PubMed  CAS  Google Scholar 

  77. Muller-Decker K. Cyclooxygenases in the skin. J Dtsch Dermatol Ges 2 (8): 668–675, 2004.

    Article  PubMed  Google Scholar 

  78. Kuzbicki L, Sarneck A, Chwirot BS. Expression of cyclooxygenase-2 in benign nevi and during human cutaneous melanoma progression. Melanoma Res 16 (1): 29–36, 2006.

    Article  PubMed  CAS  Google Scholar 

  79. Ladetto M, Vallet S, Trojan A, Dell’ Aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A, Falco P, Cavallo F, Ricca I, De Marco F, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105 (12): 4784–4791, 2005.

    Article  PubMed  CAS  Google Scholar 

  80. Sminia P, Stoter TR, van der Valk P, Elkhuizen PH, Tadema TM, Kuipers GK, Vandertop WP, Lafleur MV, Slotman BJ. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent gliobastoma multiforme. J Cancer Res Clinc Oncol 131 (10): 653–661, 2005.

    Article  CAS  Google Scholar 

  81. Buccoliero AM, Caldarella A, Arganini L, Mennonna P, Gallina P, Taddei A, Taddei GL. Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance. Neuropathology 24 (3): 201–207, 2004.

    Article  PubMed  Google Scholar 

  82. Karin MM, Hayashi Y, Inoie M, Imai Y, Ito H, Yamamoto M. COX-2 expression in retinoblastoma. Am J Opthamol 129 (3): 398–401, 2000.

    Article  Google Scholar 

  83. Dickens DS, Kozielski R, Khan J, Forus A, Cripe TP. Cyclooxygenase-2 expression in pediatric sarcoma. Pediatr Dev Pathol 5 (4): 356–364, 2002.

    Article  PubMed  CAS  Google Scholar 

  84. Lassus P, Ristimaki A, Huuhtanen R, Tukiainen E, Asko-Seljavaara S, Andersson LC, Miettinen M, Blomqvist C, Haglund C, Bohling T. Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentiation. Anticancer Res 25 (4): 2669–2674, 2005.

    PubMed  CAS  Google Scholar 

  85. Secchiro P, Barbarotto E, Gonelli A, Tiribelli M, Zerbinati C, Celeghini C, Agostinelli C, Pileri SA, Zauli G. Potential pathogenetic implication of cylcooxygenase-2 overexpression in B chronic lymphoid leukemia cells. Am J Pathol 167 (6): 1599–1607, 2005.

    Google Scholar 

  86. Hazar B, Ergin M, Sevrek E, Erdogan S, Tuncer I, Hakverdi S. Cyclooxygenase-2 (COX-2) expression in lymphoma. Leuk Lymphoma 45 (7): 1395–1399, 2004.

    Article  PubMed  CAS  Google Scholar 

  87. Li HL, Sun BZ, Ma FC. Expression of COX-2, iNOS, p. 53, and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 10 (13): 1862–1866, 2004.

    PubMed  CAS  Google Scholar 

  88. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygnease-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276 (21): 18563–18569, 2001.

    Article  PubMed  CAS  Google Scholar 

  89. Reddy BS, Rao CV. Role of synthetic and naturally occurring cyclooxygenase inhibitors in colon cancer prvention. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, pp. 71–83, 2002.

    Chapter  Google Scholar 

  90. Abou-Issa HM, Alshafie GA, Harris RE. Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, pp. 85–98, 2002.

    Chapter  Google Scholar 

  91. Schuller HM. The role of cyclooxygenase-2 in the prevention and therapy of lung cancer. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, pp. 99–116, 2002.

    Chapter  Google Scholar 

  92. Whelan J, McEntee MF. Nonsteroidal anti-inflammatory drugs, prostaglandins, and Apc-driven intestinal tumorigenesis. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, pp. 117–145,2002.

    Chapter  Google Scholar 

  93. DuBois RN, Abramson SB, Rofford L, Gupta RA, Simon LS, Van De Putte LB, Lypsky PE. Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073, 1998.

    PubMed  CAS  Google Scholar 

  94. Wu KK. Cyclooxygenase-2 induction: molecular mechanisms and pathophysiologic roles. J Lab Clin Med 128: 242–245, 1996.

    Article  PubMed  CAS  Google Scholar 

  95. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal anti-inflammatory drugs (NSAIDs). J Exp Med 190: 445–450, 1999.

    Article  PubMed  CAS  Google Scholar 

  96. Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer 8: 97–114, 2001.

    Article  PubMed  CAS  Google Scholar 

  97. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Ramonetti JT, Dannenberg AJ. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 18 (4): 795–799, 1997.

    Article  PubMed  CAS  Google Scholar 

  98. Song S, Lippman SM, Zouj Y, Ye X, Ajani JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibiton of retinoic acid receptor-beta 2 expression. Oncogene 24 (56): 8268–8276, 2005.

    Article  PubMed  CAS  Google Scholar 

  99. Karmali RA. Dietary fatty acids, COX-2 blockade, and carcinogenesis. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, pp. 3–12, 2002.

    Chapter  Google Scholar 

  100. Burd R, Choy H, Dicker A. Potential for inhibitors of cyclooxygenase-2 to enhance tumor radioresponse. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, pp. 301–311, 2002.

    Chapter  Google Scholar 

  101. Jaimes EA, Tian RX, Pearse D, Raij L. Up-regulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species. Kidney Int (5): 2143–2153, 2005.

    Google Scholar 

  102. Chang YW, Putzer K, Ren L, Kaboord B, Chance TW, Qoronfleh MW, Jakobi R. Differential regulation of cyclooxygenase 2 expression by small GTPases Ras, Rac1, and RhoA. J Cell Biochem 96(2): 314–329, 2005.

    Article  PubMed  CAS  Google Scholar 

  103. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD. Epidermal growth factor receptor activation induces nuclear targeting of cylooxygenase-2, basolateral realease of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94 (2): 657–662, 1997.

    Article  PubMed  CAS  Google Scholar 

  104. Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65 (2): 664–670, 2005.

    PubMed  CAS  Google Scholar 

  105. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 175 (12): 8242–8252, 2005.

    PubMed  CAS  Google Scholar 

  106. Konturek PC, Hartwich A, Zuchowicz M, Labza H, Pierzchalski P. Helicobacter pylori, gastrin and cyclooxygenase in gastric cancer. J Physiol Pharmacol 51 (4, Pt 1): 737–749, 2000.

    PubMed  CAS  Google Scholar 

  107. Singh A, Sharma H, Salhan S, Gupta SD, Bhatla N, Jain SK, Singh N. Evaluation of expression of apoptosis-related proteins and their correlation with HPV, telomerase activity, and apoptotic index in cervical cancer. Pathobiology 71 (6): 314–322, 2004.

    Article  PubMed  CAS  Google Scholar 

  108. Cheng AS, Chan HL, Leung WK, To KF, Go MY, Chan JY, Liew CT, Sung JJ. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 17 (10): 1169–1179, 2004.

    Article  PubMed  CAS  Google Scholar 

  109. Kaul R, Verma SC, Murakami M, Lan K, Choudhuri T, Robertson ES. Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1. J Virol 80 (3): 1321–1331, 2006.

    Article  PubMed  CAS  Google Scholar 

  110. Ji YS, XI Q, Schmedtje JF Jr. Hypoxia induced high-mobility group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ Res 83 (3): 295–304, 1998.

    PubMed  CAS  Google Scholar 

  111. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem 6(3): 221–232, 2006.

    PubMed  CAS  Google Scholar 

  112. Muller N, Riedel M, Schwarz MJ. Psychotropic effects of COX-2 inhibitors–a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37(6): 266–269, 2004.

    Article  PubMed  CAS  Google Scholar 

  113. Inoue H, Taba Y, Miwa Y, Yokota C, Miyagi M, Sasaguri T. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 22(9): 1415–1420, 2002.

    Article  PubMed  CAS  Google Scholar 

  114. Bezugla Y, Kolada A, Kamionka S, Bernard B, Scheibe R, Dieter P. COX-1 and COX-2 contribute differentially to the LPS-induced release of PGE2 and TxA2 in liver macrophages. Prostaglandins Other Lipid Mediat 79 (1–2): 93–100, 2006.

    Article  PubMed  CAS  Google Scholar 

  115. Karmali RA, Marsh J. Antitumor activity in rat mammary adenocarcinoma: effects of cyclooxygenase inhibitors and immunization against prostaglandin E2. Prostaglandins Leukotrienes and Medicine 23: 11–14, 1986.

    Article  CAS  Google Scholar 

  116. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacology and Therapeutics 83: 217–244, 1999.

    Article  PubMed  CAS  Google Scholar 

  117. Harris RE, Robertson FM, Farrar WB, Brueggemeier RW. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP-19): an extension of the dietary fat hypothesis of breast cancer. Medical Hypotheses 52 (4): 292–293, 1999.

    Article  Google Scholar 

  118. Martey CA, Baglole CJ, Gasiewicz TA, Sime PJ, Phipps RP. The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibrobasts. Am J Physiol Lung Cell Mol Physiol 289 (3): 391–399, 2005.

    Article  CAS  Google Scholar 

  119. Shin VY, Liu ES, Ye YN, Koo MW, Chu KM, Cho CH. A mechanistic study of cigarette smoke and cyclooxygenase-2 on proliferation of gastric cancer cells. Toxicol Appl Pharmacol 195(1): 103–112, 2004.

    Article  PubMed  CAS  Google Scholar 

  120. Liu ES, Shin VY, Ye YN, Luo JC, Wu WK, Cho CH. Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract. Eur J Pharmacol 518(1): 47–55, 2005.

    Article  PubMed  CAS  Google Scholar 

  121. Cakir Y, Plummer HK 3rd, Tithof PK, Schuller HM. Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol J 1: 153–157, 2002.

    Google Scholar 

  122. Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 20 (5–6): 651–656, 2002.

    Article  PubMed  CAS  Google Scholar 

  123. Izzotti A, Cartiglia C, Longobardi M, Balansky RM, D’Agostini F, Lubet RA, De Flora S. Alterations of gene expression in skin and lung of mice exposed to light and cigarette smoke. FASEB J 18 (13):1559–1561, 2004.

    PubMed  CAS  Google Scholar 

  124. Rioux N, Castonaguay A. Prevention of NNK-induced lung tumorigenesis in A? J mice by acetylsalicylic acid and NS-398. Cancer Res 58: 5354–5360, 1998.

    PubMed  CAS  Google Scholar 

  125. Castonguay A, Rioux N, Duperron C, Jalbert G. Inhibition of lung tumorigenesis by NSAIDs: a working hypothesis. Exp Lung Res 24: 605–615, 1998.

    Article  PubMed  CAS  Google Scholar 

  126. Tsai KS, Yang RS, Liu SH. Benzo[a]pyrene regulates osteoblast proliferation through an estrogen receptor-related cyclooxygenase-2 pathway. Chem Res Toxicol (5): 679–684, 2004.

    Google Scholar 

  127. Schuller HM, Plummer HK III, Bochsler PN, Dudrick P, Bell JL, Harris RE. Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinomas. Int J Oncol 19: 445–449, 2001.

    PubMed  CAS  Google Scholar 

  128. Jang B-C, Hla T. Regulation of expression and potential carcinogenic role of cylcooxygenase-2. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, pp. 3–12, 2002.

    Google Scholar 

  129. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined Analysis of COX-2 and p53 Expressions Reveals Synergistic Inverse Correlations with Microsatellite Instability and CpG Island Methylator Phenotype in Colorectal Cancer. Neoplasia 8 (6): 458–464, 2006.

    Article  PubMed  CAS  Google Scholar 

  130. Chow LW, Zhu L, Loo WT, Lui EL. Aberrant methylation of cyclooxygenase-2 in breast cancer patients. Biomed Pharmacother 59 (2): S264–267, 2005.

    Article  PubMed  CAS  Google Scholar 

  131. Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 424: 83–95, 1999.

    PubMed  CAS  Google Scholar 

  132. Hendrickse CW, Kelly RW, Radley S, Donovan IA, Beighley MRB, Neoptolemos JP. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 81: 1219–1223, 1994.

    Article  PubMed  CAS  Google Scholar 

  133. Plastara JP, Guengerich FP, Nebert DW, Marnett LJ. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatienoic acid and the mutagen, malondialdehyde. J Biol Chem 275: 11784–11790, 2000.

    Article  Google Scholar 

  134. Marnett LJ, Basu AK, O’hara SM, Weller PE, Rahman AFMM, Oliver JP. Reaction of malondialdehyde with guanine nucleosides: formation of adducts containing oxadraza-bicyclononene residues in the base-pairing region. J Am Chem Soc 108: 1348–1350, 1986.

    Article  CAS  Google Scholar 

  135. Sharma RA, Gescher A, Plastaras JP, Ceuratti C, Singh R, Gallacher-Horley B, Offord E, Marnett LJ, Steward WP, Plummer SM. Cycloxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogensis 22 (9): 1557–1560, 2001.

    Article  CAS  Google Scholar 

  136. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 (3): 289–293, 2002.

    Article  PubMed  CAS  Google Scholar 

  137. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 57 (14): 2890–2895, 1997.

    PubMed  CAS  Google Scholar 

  138. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1438 (1): 120–130, 1999.

    PubMed  CAS  Google Scholar 

  139. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 (12): 5739–5742, 1996.

    Article  PubMed  CAS  Google Scholar 

  140. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140 (1–2): 27–35, 1999.

    Article  PubMed  CAS  Google Scholar 

  141. Richards JA, Brueggemeier. Interactions of cyclooxygenase and aromatase pathways in normal and malignant breast cells. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, 2002.

    Google Scholar 

  142. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, Pietras RJ. Aromatase inhibitors in human lung cancer therapy. Cancer Res 65 (24): 11287–11291, 2005.

    Article  PubMed  CAS  Google Scholar 

  143. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol 71 (5–6): 223–230, 1999.

    Article  PubMed  CAS  Google Scholar 

  144. Ellem SJ, Risbridger GP. Aromatase and prostate cancer. Minerva Endocrinol 31 (1): 1–12, 2006.

    PubMed  CAS  Google Scholar 

  145. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9 (1): 15–21, 1999.

    Article  PubMed  CAS  Google Scholar 

  146. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2 (9): 653–660, 2000.

    Article  PubMed  CAS  Google Scholar 

  147. Clevers H. Colon cancer-understanding how NSAIDs work. NEJM 354 (7): 761–763, 2006.

    Article  PubMed  CAS  Google Scholar 

  148. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a GS-axin-beta-catenin signaling axis. Science 310: 1504–1510, 2005.

    Article  PubMed  CAS  Google Scholar 

  149. He T-C. Association of COX-2 and PPARs in carcinogenesis and chemoprevention. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, 2002.

    Google Scholar 

  150. Folkman J. Angiogenesis. Annu Rev Med 57: 1–18, 2006.

    Article  PubMed  CAS  Google Scholar 

  151. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3: 53–61, 2001.

    Article  PubMed  CAS  Google Scholar 

  152. Masferrer JL, Koki A, Seibert K, Zweifel BS, Settle SL, Woerner BM. Antiangiogenic and antitumor acivities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306–1311, 2000.

    PubMed  CAS  Google Scholar 

  153. Gupta RA, DuBois RN. Cyclooxygenase-2, prostaglandins, and colorectal carcinogenesis. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Human Press, Totowa, NJ, 2002.

    Google Scholar 

  154. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer-evidence for involvement of AP-1 and PEA3. J Biol Chem 277: 18649–18657, 2002.

    Article  PubMed  CAS  Google Scholar 

  155. Benoit V, Relic BG, Leval Xd X, Chariot A, Merville MP, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 23 (8): 1631–1635, 2004.

    Article  PubMed  CAS  Google Scholar 

  156. Tsujii M, Kuwano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336–3340, 1997.

    Article  PubMed  CAS  Google Scholar 

  157. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89 (3): 215–220, 2005.

    Article  PubMed  CAS  Google Scholar 

  158. Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS, Lee KY. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol 36 (5): 263–268, 2006.

    Article  PubMed  Google Scholar 

  159. Sun WH, Sun YL, Fang RN, Shao Y, Xu HC, Xue QP, Ding GX, Cheng YL. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol 35 (120): 707–713, 2005.

    Article  PubMed  Google Scholar 

  160. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6 (1): 181, 2006.

    Article  PubMed  CAS  Google Scholar 

  161. Kinugasa Y, Hatori M, Ito H, Jurihara Y, Ito D, Nagumo M. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 21 (8): 737–745, 2004.

    Article  PubMed  CAS  Google Scholar 

  162. Pan MR, Chuang LY, Hung WC. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 508 (3): 365–368, 2001.

    Article  PubMed  CAS  Google Scholar 

  163. Rigas B, Shiff SJ. Nonsteroidal anti-inflammatory drugs and the induction of apoptosis in colon cells: evidence for PHS-dependent and PHS-independent mechanisms. Apoptosis 4 (5): 373–381, 1999.

    Article  PubMed  CAS  Google Scholar 

  164. Battu S, Rigaud M, Beneytout JL. Resistance to apoptosis and cyclooxygenease-2 expression in a human adenocarcinoma cell line HT29 CL19A. Anticancer Res 18 (5A): 3579–3583, 1998.

    PubMed  CAS  Google Scholar 

  165. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 6 (6): 2513–2520, 2000.

    PubMed  CAS  Google Scholar 

  166. Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, Sveinbjornsson B, Kogner P. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64 (20): 7210–7215, 2004.

    Article  PubMed  CAS  Google Scholar 

  167. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493–501, 1995.

    Article  PubMed  CAS  Google Scholar 

  168. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62 (17): 4903–4908, 2002.

    PubMed  CAS  Google Scholar 

  169. Totzke G, Schulze-Osthoff K, Janicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22 (39): 8021–8030, 2003.

    Article  PubMed  CAS  Google Scholar 

  170. Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T. Cox-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18 (1): 41–47, 2006.

    PubMed  CAS  Google Scholar 

  171. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2: evidence for involvement of extracellular signal regulated kinase-jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 273: 32943–32949, 1998.

    Article  PubMed  CAS  Google Scholar 

  172. Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA. Cyclooxygense-2 inhibition sensitizes human colon carcinoma cells to Trail-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 65 (24): 11447–11458, 2005.

    Article  PubMed  CAS  Google Scholar 

  173. Staveley-O’Carroll K, Sotomayor E, Montgomery J. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95: 1178–1183, 1998.

    Article  PubMed  CAS  Google Scholar 

  174. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 11: 328–339, 2004.

    Article  PubMed  Google Scholar 

  175. Pollard M, Luckert PH. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 70: 1103–5, 1983.

    PubMed  CAS  Google Scholar 

  176. Pollard M, Luckert PH. Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 49: 6471–3, 1989.

    PubMed  CAS  Google Scholar 

  177. Reddy BS, Maruyama H, Kelloff G. Dose related inhibition of colon carcinogenisis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340–6, 1987.

    PubMed  CAS  Google Scholar 

  178. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13: 1019–23, 1992.

    Article  PubMed  CAS  Google Scholar 

  179. Karmali RA, Marsh J, Fuchs C. Effect of omega-3 fatty acids on growth of a rat mammary tumor. J Natl Cancer Inst 73: 457–461, 1984.

    PubMed  CAS  Google Scholar 

  180. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18: 1001–1006, 1997.

    Article  PubMed  CAS  Google Scholar 

  181. Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 18: 243–254, 1991.

    Article  PubMed  CAS  Google Scholar 

  182. Kelloff GJ, Steele VE, Sigman CC. Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, pp. 279–300, 2002.

    Chapter  Google Scholar 

  183. Kawamori T, Rao CV, Siebert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase 2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409–412, 1998.

    PubMed  CAS  Google Scholar 

  184. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a specific cyclooygenase-2 (COX-2) inhibitor. Cancer Res 60: 2101–2103, 2000.

    PubMed  CAS  Google Scholar 

  185. Harris RE, Beebe-Donk J, Doss H, Burr-Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (Review). Oncology Reports 13: 559–583, 2005.

    PubMed  CAS  Google Scholar 

  186. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 299: 1247–1250, 1989.

    CAS  Google Scholar 

  187. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593, 1991.

    Article  PubMed  CAS  Google Scholar 

  188. Gridley G, McLaughlin JK, Ekbom A. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307–311, 1993.

    Article  PubMed  CAS  Google Scholar 

  189. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H-O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control; study. Gastroentology 107: 117–120, 1994.

    CAS  Google Scholar 

  190. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146, 1994.

    Article  PubMed  CAS  Google Scholar 

  191. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Asherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241–246, 1994.

    PubMed  CAS  Google Scholar 

  192. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609–614, 1995.

    Article  PubMed  CAS  Google Scholar 

  193. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 14: 551–553, 1996.

    PubMed  CAS  Google Scholar 

  194. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch Intern Med 159: 161–166, 1999.

    Article  PubMed  CAS  Google Scholar 

  195. Collet JP, Sharpe C, Belzile E, Boivin J-F, Hanley J, Abenhaim L. Colorectal cancer prevention by nonsteroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81: 62–68, 1999.

    Article  PubMed  CAS  Google Scholar 

  196. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in a general practice research database. Br Med J 320: 1642–1646, 2000.

    Article  CAS  Google Scholar 

  197. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs. Epidemiology 12: 88–93, 2001.

    Article  PubMed  CAS  Google Scholar 

  198. Peleg I, Maibach H, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394–399, 1994.

    Article  PubMed  CAS  Google Scholar 

  199. Muscat J, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 74: 1847–1854, 1994.

    Article  PubMed  CAS  Google Scholar 

  200. Reeves MJ, Newcomb PA, Trentham-Diez A, Storer BE, Remington P. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 5: 955–960, 1996.

    PubMed  CAS  Google Scholar 

  201. LaVecchia C, Negri E, Francheschi S, Conti E, Montella M, Giacosa A, et al. Aspirin and colorectal cancer. Br J Cancer 76: 675–677, 1997.

    CAS  Google Scholar 

  202. Rosenberg L, Louik C, Shapiro S. Nonsteoridal anti-inflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82: 3236–33, 1998.

    Article  Google Scholar 

  203. Friedman GD, Coates AO, Potter JD, Slattery ML. Drugs and colon cancer. Pharmacoepidemol Drug Safety 7: 99–106, 1998.

    Article  CAS  Google Scholar 

  204. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 11: 249–255, 2000.

    Article  PubMed  CAS  Google Scholar 

  205. Rahme E, Barkum AN, Goubouti Y, Bardou M. The cyclooxygenase2 selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125 (2): 404–412, 2003.

    Article  PubMed  CAS  Google Scholar 

  206. Thun MJ, Henley SJ. Epidemiology of nonsteroidal anti-inflammatory drugs in colorectal cancer. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, pp. 35–55, 2002.

    Chapter  Google Scholar 

  207. Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 13 (4): 538–545, 2004.

    PubMed  CAS  Google Scholar 

  208. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327, 1993.

    PubMed  CAS  Google Scholar 

  209. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88: 988–993, 1996.

    Article  PubMed  CAS  Google Scholar 

  210. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncology Reports 6: 71–73, 1999.

    PubMed  CAS  Google Scholar 

  211. Johnson TJ, Anderson KI, Lazovich D, Folsom AR. Association of aspirin and other nonsteroidal anti-inflammatory drug use with incidence of postmenopausal breast cancer. Proc Amer Assoc Cancer Res 42: Abstract 4098, 763, 2001.

    Google Scholar 

  212. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascensco JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research 63: 6096–6101, 2003.

    PubMed  CAS  Google Scholar 

  213. Harris RE, Namboodiri KK, Farrar WB. Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer. Oncology Reports 2: 591–592, 1995.

    Google Scholar 

  214. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 24: 107–109, 1995.

    Article  PubMed  CAS  Google Scholar 

  215. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7: 203–205, 1996.

    Article  PubMed  CAS  Google Scholar 

  216. Neuget AI, Rosenbert DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarker Prev 7: 869–873, 1998.

    Google Scholar 

  217. Coogan PF, Rao Sr, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29 (2): 72–76, 1999.

    Article  PubMed  CAS  Google Scholar 

  218. Sharpe CR, Collet JP, McNutt M, Belzille E, Boivin JF, Hanley JA. Nested case control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Can 83: 112–120, 2000.

    Article  CAS  Google Scholar 

  219. Cotterchio M, Kreiger N, Steingart A, Buchan G. Nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer. SER Abstract, Amer J Epidemiol 151: S72, 2000.

    Google Scholar 

  220. Langman MJ, Chen KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on the overall risk of common cancer: case control study in general practice research database. Br Med J 320: 1642–1646, 2000.

    Article  CAS  Google Scholar 

  221. Meier CR, Schmitz S, Jeck H. Association between acetaminophen or nonsteroidal anti-inflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22 (3): 303–309, 2002.

    Article  PubMed  CAS  Google Scholar 

  222. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between nonsteroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes and Control 14: 915–922, 2003.

    Article  PubMed  Google Scholar 

  223. Terry MB, Gammon MD, Zang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neuget AI. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291 (20): 2433–2440, 2004.

    Article  PubMed  CAS  Google Scholar 

  224. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 162 (2): 165–170, 2005.

    Article  PubMed  Google Scholar 

  225. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296 (6618): 313–316, 1988.

    CAS  Google Scholar 

  226. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by nonsteroidal anti-inflammatory drugs among cigarette smokers. Oncology Reports 9: 693–695, 2002.

    PubMed  CAS  Google Scholar 

  227. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE. Aspirin and lung cancer in women. Br J Cancer 87 (11): 1337–1338, 2002.

    Article  CAS  Google Scholar 

  228. Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loween GM, Bepler G. Regular aspirin use and lung cancer risk. BMC Cancer 2(1): 31, 2002.

    Article  PubMed  Google Scholar 

  229. Holick CN, Michaud DS, Leitzmann MF, Willett WC, Giovannucci E. Aspirin use and lung cancer in men. Br J Cancer 89 (9): 1705–1708, 2003.

    Article  PubMed  CAS  Google Scholar 

  230. Muscat JE, Chen SQ, Richie JP Jr, Altorki NK, Citron M, Olson S, Neugut AI, Stellman SD. Risk of lung carcinoma among users of nonsteroidal anti-inflammatory drugs. Cancer 97 (7): 1732–1736, 2003.

    Article  PubMed  Google Scholar 

  231. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77 (3): 219–225, 2002.

    PubMed  Google Scholar 

  232. Leitzman MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (101): 1108–1111, 2002.

    Google Scholar 

  233. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13 (5): 427–434, 2002.

    Article  PubMed  Google Scholar 

  234. Nelson JE, Harris RE. Inverse association of prostate cancer and nonsteroidal anti-inflammatory drugs (NSAIDs): results of a case control study. Oncology Reports 7: 169–170, 2000.

    PubMed  CAS  Google Scholar 

  235. Norrish AE, Jackson RT, McRae CU. Nonsteroidal anti-inflammatory drugs and prostate cancer progression. International Journal of Cancer 77: 511–515, 1998.

    Article  CAS  Google Scholar 

  236. Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautar D, Coloby P, Fontaine E, Bladou F, Desgradnchampls F, Lahillot O. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 168 (5): 1985–1988, 2002.

    Article  PubMed  CAS  Google Scholar 

  237. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal anti-inflammatory drug use and risk of prostate cancer. Int J Cancer 106 (3): 409–415, 2003.

    Article  PubMed  CAS  Google Scholar 

  238. Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13 (4): 649–653, 2004.

    PubMed  CAS  Google Scholar 

  239. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 76 (7): 1116–1119, 1995.

    Article  PubMed  CAS  Google Scholar 

  240. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophpageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7 (2): 97–102, 1998.

    PubMed  CAS  Google Scholar 

  241. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothaki V, Trichopoulos D. Lifestyle factors and medical condition in relation to esophageal cancer by histologic type in a low risk population. Int J Cancer 68 (3): 295–299, 1996.

    Article  PubMed  CAS  Google Scholar 

  242. Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mosaffari P, Ahmed A, Day NE. A case control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 83 (1): 127–132, 2000.

    Article  PubMed  CAS  Google Scholar 

  243. Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL, Schoenberg JB, Mayne ST, Stanford JL, Dubrow R, Rotterdam H, West AB, Fraumeni JF Jr, Weinstein IB, Hibshoosh H. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiology, Biomarkers & Prevention 13: 34–39, 2004.

    Article  CAS  Google Scholar 

  244. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JM, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7 (2): 97–102, 1998.

    PubMed  CAS  Google Scholar 

  245. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 9 (1): 119–123, 2000.

    PubMed  CAS  Google Scholar 

  246. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 82 (4): 473–476, 1998.

    Article  Google Scholar 

  247. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 84 (7): 965–968, 2001.

    Article  PubMed  CAS  Google Scholar 

  248. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association of aspirin and other nonsteroidal anti-inflammatory drug use with incidence of pancreatic cancer in a cohort of postmenopausal women. Proc Amer Assoc Cancer Res, 92d Ann Meeting, Abstract 4095, 42: 763, 2001.

    Google Scholar 

  249. Menezes RJ, Huber KR, Mahoney MC, Moysich KB. Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2(1): 18, 2002.

    Article  PubMed  Google Scholar 

  250. Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, Colditz GA, Fuchs CS. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96: 22–28, 2004.

    Article  PubMed  CAS  Google Scholar 

  251. Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96 (7): 524–528, 2004.

    Article  PubMed  CAS  Google Scholar 

  252. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 13 (6): 535–542, 2002.

    Article  PubMed  Google Scholar 

  253. Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 44 (3): 408–410, 1993.

    Article  Google Scholar 

  254. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greer ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 351 (9096): 104–1097, 1998.

    Article  PubMed  CAS  Google Scholar 

  255. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer, and Italian case-control study. Ann Oncol 11 (9): 1171–1173, 2000.

    Article  PubMed  CAS  Google Scholar 

  256. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Shapiro S. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev (9): 933–937, 2000.

    PubMed  CAS  Google Scholar 

  257. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 10(8): 903–906, 2001.

    PubMed  CAS  Google Scholar 

  258. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koening KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med 33 (6): 682–687, 2001.

    Article  PubMed  CAS  Google Scholar 

  259. Lacey JV, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 108: 281–286, 2004.

    Article  PubMed  CAS  Google Scholar 

  260. Castelao JE, Yuan J-M, Gago-Dominguez, Yu MC, Ross RK. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. British J Cancer 82(7): 1364–1369, 2000.

    Article  CAS  Google Scholar 

  261. McCredie M, Ford J, Taylor JS, Stewart JH. Analgesics and cancer of the renal pelvis in New South Wales. Cancer 49 (12): 2617–2725, 1982.

    Article  PubMed  CAS  Google Scholar 

  262. McCredie M, Stewart JH, Fort JM. Analgesics and tobacco as risk factors for cancers of the ureter and renal pelvis. J Urol 130 (1): 28–30, 1983.

    PubMed  CAS  Google Scholar 

  263. McLaughlin KJ, Blot WJ, Mehl ES, Fraumeni JF Jr. Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr 69: 217–222, 1985.

    PubMed  CAS  Google Scholar 

  264. Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE. Analgesics, cigarette smoking, and other risk factors for cancers of the renal pelvis and ureter. Cancer Res 49 (4): 1045–1048, 1989.

    PubMed  CAS  Google Scholar 

  265. Chow WH, McLaughlin KJ, Linet MS, Niwa S, Madel JS. Use of analgesics and risk of renal cell cancer. Int J Cancer 59 (4): 467–470, 1994.

    Article  PubMed  CAS  Google Scholar 

  266. Derby LE, Jick H. Acetaminophen and bladder cancer. Epidemiology 7 (4): 358–362, 1996.

    Article  PubMed  CAS  Google Scholar 

  267. Jensen OM, Knudsen JB, Tomasson H, Sorensen BL. The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. Int J Cancer 44 (6): 965–968, 1989.

    Article  PubMed  CAS  Google Scholar 

  268. Rosenberg L, Rao RS, Palmer JR, Strom BL, Zauber A, Warshauer ME, Stolley PD, Shapiro S. Transitional cell cancer of the urinary tract and renal cell cancer: relation to acetaminophen use (United States). Cancer Causes Control 9 (1): 83–88, 1998.

    Article  PubMed  CAS  Google Scholar 

  269. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 81 (3): 542–548, 1999.

    Article  PubMed  CAS  Google Scholar 

  270. Linet MS, Chow WH, McLaughlin JK, Wacholder S, Yu MC, Schoenberg JB, Lynch C, Fraumeni JF Jr. Analgesics and cancers of the renal pelvis and ureter. Int J Cancer 62 (1): 15–18, 1995.

    Article  PubMed  CAS  Google Scholar 

  271. McCredie M, Pommer W, McLaughlin JK, Stewart JH, Lindblad P, Mandel JS, Mellemgaard A, Schlehofer B, Niwa S. International renal cell cancer study. II. Analgesics. Int J Cancer 60 (3): 345–349, 1995.

    PubMed  CAS  Google Scholar 

  272. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumor sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 14 (12): 2892–2997, 1999.

    Article  PubMed  CAS  Google Scholar 

  273. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of nonsteroidal anti-inflammatory drugs and malignant melanoma among women. Oncology Reports 8: 655–657, 2001.

    PubMed  CAS  Google Scholar 

  274. Prior P, Symmons DPM, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 43: 128–131, 1984.

    Article  PubMed  CAS  Google Scholar 

  275. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85 (4): 258–259, 1993.

    Article  Google Scholar 

  276. Cerhan JR, Wallace RB, Folsom AR, Potter JD, Sellers TA, Zheng W, Langley CT. Medical history risk factors for non-Hodgkins’s lymphoma in older women. J Natl Cancer Inst 89 (11): 816–817, 1997.

    Article  Google Scholar 

  277. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and risk of cancer. Ugeskr Laeger 160 (21): 3069–3073, 1998.

    PubMed  CAS  Google Scholar 

  278. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88 (3): 497–502, 2000.

    Article  PubMed  CAS  Google Scholar 

  279. Tavani A, La Vecchia C , Franceschi S, Serraino D, Carbone A. Medical history and risk of Hodgkin’s and non-Hodgkin’s lymphomas. Eur J Cancer Prev 9 (1): 59–64, 2000.

    Article  PubMed  CAS  Google Scholar 

  280. Baecklund E, Ekbom A, Sparen P, Fetelius N, Kareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317: 180–181, 1998.

    PubMed  CAS  Google Scholar 

  281. Tennis P, Andrews E, Bombardier C, Wang Y, Strand L, West R, Tilson R, Doi P. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada. J Clin Epidemiol 46 (7): 685–695, 1993.

    Article  PubMed  CAS  Google Scholar 

  282. Bendix G, Bjell A, Holmberg E. Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold. Scand J Rheumatol 24 (2): 79–84, 1995.

    PubMed  CAS  Google Scholar 

  283. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 35 (8): 738–745, 1996.

    Article  PubMed  CAS  Google Scholar 

  284. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin’s lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52 (19): 5510–5515, 1992.

    Google Scholar 

  285. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, HabermannTM. Association of aspirin and other nonsteroidal anti-inflammatory drug use with incidence of non-Hodgkin’s lymphoma, Int J Cancer 106: 784–788, 2003.

    Article  PubMed  CAS  Google Scholar 

  286. Kato I, Koenig KL, Shore RE, Baptiste MS, Lillquist PP, Grizzera G, Burke JS, Watanabe H. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin’s lymphoma (NHL) (United States). Cancer Causes and Control 13: 965–974, 2002.

    Article  PubMed  Google Scholar 

  287. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin’s lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150 (4): 375–389, 1999.

    PubMed  CAS  Google Scholar 

  288. Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE. Aspirin and the risk of Hodgkin’s lymphoma in a population-based case-control study. J Natl Cancer Inst 96 (4): 305–315, 2004.

    Article  PubMed  CAS  Google Scholar 

  289. Kasum CM, Blair CK, Folsom AR, Ross JA. Nonsteroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomarkers Prev 12 (6): 534–537, 2003.

    PubMed  CAS  Google Scholar 

  290. Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni JF Jr. Prior medical conditions and the risk of adult leukemia in Shanghai People’s Republic of China. Cancer Causes Control 4 (4): 361–368, 1993.

    Article  PubMed  CAS  Google Scholar 

  291. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3: 28, 2003.

    Article  PubMed  Google Scholar 

  292. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 24: 83–7, 1983.

    Article  PubMed  CAS  Google Scholar 

  293. Giardiello FM. NSAID-induced polyp regression in Familial Adenomatous Polyposis patients. Gastroenterology Clinics of North America 25: 349–61, 1996

    Article  PubMed  CAS  Google Scholar 

  294. Suh O, Mettlin C, Petrelli N. Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171–1177, 1993.

    Article  PubMed  CAS  Google Scholar 

  295. Peleg I, Maibach H, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394–399, 1994.

    Article  PubMed  CAS  Google Scholar 

  296. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk of large bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 85: 912–916, 1993.

    Article  PubMed  CAS  Google Scholar 

  297. Logan RF, Litte J, Hawtin PG, Hardcastle JD. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening program. BMJ 307: 285–289, 1993.

    Article  PubMed  CAS  Google Scholar 

  298. Martinez M, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 4: 703–707, 1995.

    PubMed  CAS  Google Scholar 

  299. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 114: 441–448, 1998.

    Article  PubMed  CAS  Google Scholar 

  300. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Breuer N, et al. Long-term use of nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 61: 129–134, 2000.

    Article  PubMed  CAS  Google Scholar 

  301. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Troussett M, Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635–639, 1991.

    PubMed  CAS  Google Scholar 

  302. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus JA. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313–6, 1993.

    Article  PubMed  CAS  Google Scholar 

  303. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80: 1618–9, 1993.

    Article  PubMed  CAS  Google Scholar 

  304. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (Feb 20): 252–266, 2002.

    PubMed  CAS  Google Scholar 

  305. Anderson WF, Umar A, Viner JL, Hawk ET. Potential role of NSAIDs in COX-2 blockade in cancer therapy. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, pp. 313–340, 2002.

    Chapter  Google Scholar 

  306. Steinbach G, Lynch PM, Phillips RK, Wallace MB, Hawk E, Gordon G, al et. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl J Med 342: 1946–52. 2000.

    Article  PubMed  CAS  Google Scholar 

  307. Bertagnolli MM, Eagle CJ, Hawk ET. Celecoxib recduces spradic colrectal adenomas: results from the Adenoma Prevention with Celecoxib (APC) trial. American Association for Cancer Research, 97th Annual Meeting, Abstract CP-3, page 186, 2006.

    Google Scholar 

  308. Arber N, Racz I, Spicak J, Zavoral M, Lechuga MJ, Gerletti P, Eagle CJ, Levin B. Chemoprevention of colorectal adenomas with celecoxib in an international randomized, placebo-controlled, double-blind trial. American Association for Cancer Research, 97th Annual Meeting, Abstract CP-4, page 186, 2006.

    Google Scholar 

  309. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF Jr. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in orpharyngeal leukoplakia. Clin Cancer Res 10 (5): 1565–1671, 2004.

    Article  PubMed  CAS  Google Scholar 

  310. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadofilopoulos G. Rofecoxib inhibits cyclooxygenase-2 expression and activity and reduces cell proliferation in Barrett’s esophagus. Gastroenterology 123 (1):60–67, 2002.

    Article  PubMed  CAS  Google Scholar 

  311. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (8): 954–959, 2001.

    Article  PubMed  CAS  Google Scholar 

  312. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooygenase-2 (COX-2) inhibitors. BMC Cancer 6: 27, 2006.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Medicine and School of Public Health, Center of Molecular Epidemiology and Environmental Health, The Ohio State University Medical Center, 310 West 10th Avenue,Columbus, Ohio 43210-1240

    Randall E. Harris

Authors
  1. Randall E. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center of Molecular Epidemiology and Environmental Health, College of Medicine and School of Public Health, The Ohio State University Medical Center, Columbus, Ohio, USA

    Randall E. Harris (Director) (Director)

  2. Queens College, City University of New York, New York, USA

    R. Bittman

  3. Saha Institute of Nuclear Physics, Calcutta, India

    D. Dasgupta

  4. Max-Planck-Institute for Biochemistry, Munich, Germany

    H. Engelhardt

  5. MOLISA GmbH, Magdeburg, Germany

    L. Flohe

  6. German Cancer Research Center, Heidelberg, Germany

    H. Herrmann

  7. Texas A&M University, Texas, USA

    A. Holzenburg

  8. National University of Ireland, Galway, Ireland

    H-P. Nasheuer

  9. The Hebrew University, Jerusalem, Israel

    S. Rottem

  10. DSM Nutritional Products Ltd., Basel, Switzerland

    M. Wyss

  11. Max-Planck-Institute for Biochemistry, Munich, Germany

    P. Zwickl

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Harris, R.E. (2007). Cyclooxygenase-2 (COX-2) and the Inflammogenesis of Cancer. In: Harris, R.E., et al. Inflammation in the Pathogenesis of Chronic Diseases. Subcellular Biochemistry, vol 42. Springer, Dordrecht. https://doi.org/10.1007/1-4020-5688-5_4

Download citation

Publish with us

Policies and ethics

Search

Navigation